BIO-RAD LABORATORIES, INC.

BIO-B

$9.72B

Mid Cap

NASDAQBiotechnology🇺🇸North America7.7K employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 30, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

9 upcoming, 0 past

⭐Phase 3Next

PJ009 Phase 3 Results Expected

Mar 30, 2026PJ00972

Primary completion for PJ009 trial (NCT06512584) in Short Bowel Syndrome

Source

Phase 2

BAT8008 injection Phase 2 Results Expected

Apr 3, 2026BAT8008 injection112

Primary completion for BAT8008 injection trial (NCT06341114) in Advanced Solid Tumors

Source

⭐Phase 3

FDA018-ADC Phase 3 Results Expected

Aug 18, 2026FDA018-ADC350

Primary completion for FDA018-ADC trial (NCT06519370) in Triple Negative Breast Cancer

Source

Phase 2

rhPRG4 450ug/ml Phase 2 Results Expected

September 2026~rhPRG4 450ug/ml15

Primary completion for rhPRG4 450ug/ml trial (NCT07118254) in Ocular Graft Versus Host Disease

Source

Phase 2

TOUR006 - 20 MG Phase 2 Results Expected

September 2026~TOUR006 - 20 MG81

Primary completion for TOUR006 - 20 MG trial (NCT06088979) in Thyroid Eye Disease

Source

Phase 2

TRIV-509 Phase 2 Results Expected

October 2026~TRIV-50990

Primary completion for TRIV-509 trial (NCT07167758) in Atopic Dermatitis

Source

Phase 2

BAT8010 for Injection Phase 2 Results Expected

Nov 9, 2026BAT8010 for Injection216

Primary completion for BAT8010 for Injection trial (NCT06376136) in Advanced Solid Tumors

Source

⭐Phase 3

KN026 Phase 3 Results Expected

Dec 16, 2026KN026520

Primary completion for KN026 trial (NCT06747338) in Early or Locally Advanced HER2-positive Breast Cancer

Source

Phase 2

autologous dendritic cells Phase 2 Results Expected

Dec 30, 2026autologous dendritic cells24

Primary completion for autologous dendritic cells trial (NCT04115761) in GBM

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Erythropoietin alfa

Phase 3

Anemia of Chronic Kidney Disease

SARS-CoV-2 vaccine (inactivated)

Phase 3

SARS-CoV2 Infection

PJ009

Phase 3

Short Bowel Syndrome

CDFR0612

Phase 3

Colonoscopy Preparation

Tadekinig alfa

Phase 3

XIAP Deficiency

MCS-2

Phase 3

Lower Urinary Tract Symptoms

FDA018-ADC

Phase 3

Triple Negative Breast Cancer

Antiscorpion venom serum(AScVS).

Phase 3

Scorpion Envenomation

NH002 (Perflutren Lipid Microspheres) Injectable Suspension

Phase 3

Cardiac Diseases

OCA

Phase 3

PBC

AB103 0.5 mg/kg

Phase 3

Necrotizing Soft Tissue Infections

FG-4592

Phase 3

Anemia

buntanetap/posiphen

Phase 3

Parkinson's Disease (PD)

KN026

Phase 3

Early or Locally Advanced HER2-positive Breast Cancer

teplizumab

Phase 3

Type 1 Diabetes Mellitus

H002

Phase 2

Non-small Cell Lung Cancer

2.5mg of BAT5906

Phase 2

Diabetic Macular Edema

JMT108

Phase 2

Advanced Malignant Tumors

Verekitug (UPB-101)

Phase 2

Severe Asthma

QLS-101ophthalmic solution 1%

Phase 2

Sturge-Weber Syndrome (SWS)

rhPRG4 450ug/ml

Phase 2

Ocular Graft Versus Host Disease

PolyPEPI1018

Phase 2

Colorectal Cancer Metastatic

TOUR006 - 20 MG

Phase 2

Thyroid Eye Disease

Aminolaevulinic acid photodynamic therapy

Phase 2

Cervical Persistent High Risk HPV Infection

AVB-114

Phase 2

Perianal Fistula

KAN-101

Phase 2

Celiac Disease

BAT8010 for Injection

Phase 2

Advanced Solid Tumors

AXER-204

Phase 2

Chronic Spinal Cord Injury

Allogeneic umbilical cord mesenchymal stem cells

Phase 2

Multiple Sclerosis

U32 CAR-T

Phase 2

Acute Myeloid Leukaemia

BGM0504

Phase 2

Overweight or Obesity

autologous dendritic cells

Phase 2

GBM

human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection

Phase 2

Parkinson Disease (PD)

TER-101

Phase 2

Atopic Dermatitis

PRX302

Phase 2

Benign Prostatic Hyperplasia

TRIV-509

Phase 2

Atopic Dermatitis

pegylated recombinant human arginase

Phase 2

Hepatocellular Carcinoma

Vi-DT Vaccine

Phase 2

Safety Issues

INX-315

Phase 2

Breast Cancer

Eprotirome

Phase 2

Primary Hypercholesterolemia

TBI-1501

Phase 2

Lymphoblastic Leukemia, Acute Adult

ADSTEM Inj.

Phase 2

Atopic Dermatitis

SB1518

Phase 2

Myelofibrosis

BAT8008 injection

Phase 2

Advanced Solid Tumors

TOUR006 - 50 MG

Phase 2

Chronic Kidney Diseases

CGB-500 with 0.5% tofacitinib

Phase 2

Atopic Dermatitis (AD)

OCE-205

Phase 2

Cirrhosis

Tadekinig alfa (recombinant human IL-18 binding protein)

Phase 2

Still's Disease, Adult-Onset

Pegylated Recombinant Human Arginase I

Phase 2

Neoplasm

PACOX

Phase 2

Hepatocellular Carcinoma

Drug Name	Phase	Indication	Designations
Erythropoietin alfa	Phase 3	Anemia of Chronic Kidney Disease	-
SARS-CoV-2 vaccine (inactivated)	Phase 3	SARS-CoV2 Infection	-
PJ009	Phase 3	Short Bowel Syndrome	-
CDFR0612	Phase 3	Colonoscopy Preparation	-
Tadekinig alfa	Phase 3	XIAP Deficiency	-
MCS-2	Phase 3	Lower Urinary Tract Symptoms	-
FDA018-ADC	Phase 3	Triple Negative Breast Cancer	-
Antiscorpion venom serum(AScVS).	Phase 3	Scorpion Envenomation	-
NH002 (Perflutren Lipid Microspheres) Injectable Suspension	Phase 3	Cardiac Diseases	-
OCA	Phase 3	PBC	-
AB103 0.5 mg/kg	Phase 3	Necrotizing Soft Tissue Infections	-
FG-4592	Phase 3	Anemia	-
buntanetap/posiphen	Phase 3	Parkinson's Disease (PD)	-
KN026	Phase 3	Early or Locally Advanced HER2-positive Breast Cancer	-
teplizumab	Phase 3	Type 1 Diabetes Mellitus	-
H002	Phase 2	Non-small Cell Lung Cancer	-
2.5mg of BAT5906	Phase 2	Diabetic Macular Edema	-
JMT108	Phase 2	Advanced Malignant Tumors	-
Verekitug (UPB-101)	Phase 2	Severe Asthma	-
QLS-101ophthalmic solution 1%	Phase 2	Sturge-Weber Syndrome (SWS)	-
rhPRG4 450ug/ml	Phase 2	Ocular Graft Versus Host Disease	-
PolyPEPI1018	Phase 2	Colorectal Cancer Metastatic	-
TOUR006 - 20 MG	Phase 2	Thyroid Eye Disease	-
Aminolaevulinic acid photodynamic therapy	Phase 2	Cervical Persistent High Risk HPV Infection	-
AVB-114	Phase 2	Perianal Fistula	-
KAN-101	Phase 2	Celiac Disease	-
BAT8010 for Injection	Phase 2	Advanced Solid Tumors	-
AXER-204	Phase 2	Chronic Spinal Cord Injury	-
Allogeneic umbilical cord mesenchymal stem cells	Phase 2	Multiple Sclerosis	-
U32 CAR-T	Phase 2	Acute Myeloid Leukaemia	-
BGM0504	Phase 2	Overweight or Obesity	-
autologous dendritic cells	Phase 2	GBM	-
human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection	Phase 2	Parkinson Disease (PD)	-
TER-101	Phase 2	Atopic Dermatitis	-
PRX302	Phase 2	Benign Prostatic Hyperplasia	-
TRIV-509	Phase 2	Atopic Dermatitis	-
pegylated recombinant human arginase	Phase 2	Hepatocellular Carcinoma	-
Vi-DT Vaccine	Phase 2	Safety Issues	-
INX-315	Phase 2	Breast Cancer	-
Eprotirome	Phase 2	Primary Hypercholesterolemia	-
TBI-1501	Phase 2	Lymphoblastic Leukemia, Acute Adult	-
ADSTEM Inj.	Phase 2	Atopic Dermatitis	-
SB1518	Phase 2	Myelofibrosis	-
BAT8008 injection	Phase 2	Advanced Solid Tumors	-
TOUR006 - 50 MG	Phase 2	Chronic Kidney Diseases	-
CGB-500 with 0.5% tofacitinib	Phase 2	Atopic Dermatitis (AD)	-
OCE-205	Phase 2	Cirrhosis	-
Tadekinig alfa (recombinant human IL-18 binding protein)	Phase 2	Still's Disease, Adult-Onset	-
Pegylated Recombinant Human Arginase I	Phase 2	Neoplasm	-
PACOX	Phase 2	Hepatocellular Carcinoma	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

BIO-B News